GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NewcelX NCEL · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.78

+2.21%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About NewcelX

Its shares trade under the ticker NCEL. It has been listed since 29 January 2021.

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Jan 2021
Employees
2
Head office
THE CIRCLE 6, ZURICH
Incorporated in
V8
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Ronald HafnerIndependent Chairman of the Board$22,000
  • Mr. Alexander ZwyerChief Executive Officer, Director, since 2015$610,000
  • Ms. Nicole Fernandez-mcgovernChief Financial Officer$54,000
  • Dr. Eric KonofalChief Scientific Officer$108,000
  • Ms. Florence AkninIndependent Director$12,000
  • Mr. Gian-Marco RinaldiIndependent Director$14,000
  • Mr. Olivier SamuelIndependent Director
  • Ms. Cindy RizzoInvestor Relations, since 2020

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
42
Environment
45
Social
48
Governance
33
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • NewcelX AG focuses on neurobehavioral and neurocognitive disorder treatments with two employees.
  • NLS Pharmaceutics Ltd. serves global customers with clinical-stage biopharmaceutical products.
  • The company's IPO on 29 January 2021 established a public market presence.

Weaknesses

  • Only two full-time employees limit operational capacity and scalability.
  • Headquartered in Zurich, Zuerich, the company has limited geographic diversity.
  • Clinical-stage development requires significant future funding for growth.

Opportunities

  • Expanding into global markets for neurobehavioral disorder treatments.
  • Potential partnerships with larger pharmaceutical firms for development.
  • Growing demand for neurocognitive disorder therapies worldwide.

Threats

  • High competition in the pharmaceutical industry for neurobehavioral treatments.
  • Regulatory challenges in clinical-stage drug development processes.
  • Dependence on future funding for continued research and development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.